687 related articles for article (PubMed ID: 33483292)
1. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
Iglesias-Lopez C; Obach M; Vallano A; Agustí A
Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
[TBL] [Abstract][Full Text] [Related]
2. Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe.
Farkas AM; Mariz S; Stoyanova-Beninska V; Celis P; Vamvakas S; Larsson K; Sepodes B
Front Med (Lausanne); 2017; 4():53. PubMed ID: 28560211
[TBL] [Abstract][Full Text] [Related]
3. Regulatory Aspects for Approval of Advanced Therapy Medicinal Products in the EU.
Fürst-Ladani S; Bührer A; Fürst W; Schober-Ladani N
Handb Exp Pharmacol; 2024; 284():367-387. PubMed ID: 37017789
[TBL] [Abstract][Full Text] [Related]
4. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
[TBL] [Abstract][Full Text] [Related]
5. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.
Coppens DGM; de Wilde S; Guchelaar HJ; De Bruin ML; Leufkens HGM; Meij P; Hoekman J
Cytotherapy; 2018 Jun; 20(6):769-778. PubMed ID: 29730080
[TBL] [Abstract][Full Text] [Related]
6. Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products.
Cuende N; Ciccocioppo R; Forte M; Galipeau J; Ikonomou L; Levine BL; Srivastava A; Zettler PJ
Cytotherapy; 2022 Jul; 24(7):686-690. PubMed ID: 35545453
[TBL] [Abstract][Full Text] [Related]
7. Call for More Effective Regulation of Clinical Trials with Advanced Therapy Medicinal Products Consisting of or Containing Genetically Modified Organisms in the European Union.
Beattie S;
Hum Gene Ther; 2021 Oct; 32(19-20):997-1003. PubMed ID: 33843251
[TBL] [Abstract][Full Text] [Related]
8. EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation.
Detela G; Lodge A
Mol Ther Methods Clin Dev; 2019 Jun; 13():205-232. PubMed ID: 30815512
[TBL] [Abstract][Full Text] [Related]
9. A detailed analysis of expedited regulatory review time of marketing authorization applications for new anticancer drugs in the US and EU.
da Costa Gonçalves F; Demirci E; Zwiers A
Clin Transl Sci; 2022 Aug; 15(8):1959-1967. PubMed ID: 35561071
[TBL] [Abstract][Full Text] [Related]
10. Methodological Characteristics of Clinical Trials Supporting the Marketing Authorisation of Advanced Therapies in the European Union.
Iglesias-Lopez C; Agustí A; Vallano A; Obach M
Front Pharmacol; 2021; 12():773712. PubMed ID: 34916948
[TBL] [Abstract][Full Text] [Related]
11. Flexible and Expedited Regulatory Review Processes for Innovative Medicines and Regenerative Medical Products in the US, the EU, and Japan.
Nagai S
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31382625
[TBL] [Abstract][Full Text] [Related]
12. Post-marketing authorisation safety and efficacy surveillance of advanced therapy medicinal products in Brazil, the European Union, the United States and Japan.
Gomes KLG; da Silva RE; da Silva JB; Bosio CGP; Novaes MRCG
Cytotherapy; 2023 Oct; 25(10):1113-1123. PubMed ID: 37436339
[TBL] [Abstract][Full Text] [Related]
13. Advanced Therapy medicinal products for autologous chondrocytes and comparison of regulatory systems in target countries.
Kim J; Park J; Song SY; Kim E
Regen Ther; 2022 Jun; 20():126-137. PubMed ID: 35582708
[TBL] [Abstract][Full Text] [Related]
14. Hurdles of environmental risk assessment procedures for advanced therapy medicinal products: comparison between the European Union and the United States.
Iglesias-Lopez C; Obach M; Vallano A; Agustí A; Montané J
Crit Rev Toxicol; 2019 Aug; 49(7):580-596. PubMed ID: 31846383
[TBL] [Abstract][Full Text] [Related]
15. EU decision-making for marketing authorization of advanced therapy medicinal products: a case study.
de Wilde S; Coppens DGM; Hoekman J; de Bruin ML; Leufkens HGM; Guchelaar HJ; Meij P
Drug Discov Today; 2018 Jul; 23(7):1328-1333. PubMed ID: 29574211
[TBL] [Abstract][Full Text] [Related]
16. Hurdles in clinical implementation of academic advanced therapy medicinal products: A national evaluation.
de Wilde S; Veltrop-Duits L; Hoozemans-Strik M; Ras T; Blom-Veenman J; Guchelaar HJ; Zandvliet M; Meij P
Cytotherapy; 2016 Jun; 18(6):797-805. PubMed ID: 27068764
[TBL] [Abstract][Full Text] [Related]
17. The Current State of Advanced Therapy Medicinal Products in the Czech Republic.
Kočí Z; Boráň T; Krůpa P; Kubinová Š
Hum Gene Ther Clin Dev; 2018 Sep; 29(3):132-147. PubMed ID: 29869533
[TBL] [Abstract][Full Text] [Related]
18. Comparison of new Brazilian legislation for the approval of advanced therapy medicinal products with existing systems in the USA, European Union and Japan.
Gomes KLG; da Silva RE; da Silva Junior JB; Novaes MRCG
Cytotherapy; 2022 May; 24(5):557-566. PubMed ID: 35227603
[TBL] [Abstract][Full Text] [Related]
19. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
Pflieger M; Bertram D
Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
[TBL] [Abstract][Full Text] [Related]
20. Regulatory Framework for Advanced Therapy Medicinal Products in Europe and United States.
Iglesias-López C; Agustí A; Obach M; Vallano A
Front Pharmacol; 2019; 10():921. PubMed ID: 31543814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]